Comparative Pharmacology
Head-to-head clinical analysis: PAMELOR versus PERTOFRANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PAMELOR versus PERTOFRANE.
PAMELOR vs PERTOFRANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nortriptyline, the active ingredient, is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at the presynaptic neuronal membrane, increasing their availability in the synaptic cleft.
Tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at the presynaptic neuronal membrane, increasing their concentrations in the synaptic cleft.
25-150 mg orally per day, typically as a single daily dose at bedtime or in divided doses; start at 25 mg 1-3 times daily and titrate gradually. Maximum 150 mg/day.
150-300 mg oral in divided doses per day; 75-150 mg IM in divided doses per day
None Documented
None Documented
Mean terminal elimination half-life is 18-24 hours (range 13-40 hours) in adults; prolonged in elderly and hepatic impairment (up to 60 hours). Steady-state achieved in 4-5 days.
Terminal elimination half-life is 14–21 hours. Steady-state is reached within 5–7 days. The half-life is prolonged in elderly and patients with hepatic impairment.
Primarily renal (approximately 70% as metabolites, 40-50% as glucuronide conjugates, 20-30% as free or conjugated nortriptyline; <5% unchanged), with 20-30% biliary/fecal elimination.
Primarily renal (70%), with 30% as unchanged drug; remainder as glucuronide and sulfate conjugates. Biliary/fecal excretion accounts for <5%.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant